Fundraising Fox
/Companies
Sign in

Oragenics

NYSE: OGEN

Tampa, US · Florida corporation

Find your way into Oragenics

Each arrow is one introduction. Sign up to fill in the first one.

156 people can intro you to Alan

Ask Avery Sonnenberg to introduce you to Alan Joslyn

You →Avery · together at Inimmune →Alan

Sign up to find every way you can get introduced to Oragenics

  • Your email: who you already know at Oragenics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Oragenics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Oragenics develops treatments for concussion and traumatic brain injury, focusing on clinical development of therapeutic candidates. The company combines neuroscience expertise with healthcare operational leadership to advance solutions for brain injury treatment.

BiotechDeep TechDigital HealthLongevityMedical Devices

Founders & leadership

AJAlan Joslyn
Alan JoslynChief Executive Officer2016–2021Alan Joslyn has held executive leadership roles spanning over 2.5 years as CEO of Inimmune and prior experience at Lazarus Pharmaceuticals, where he focused on gastroenterology asset acquisition. His background includes expertise in navigating preclinical-to-clinical drug development transitions, corporate development in biotech, and capital markets strategy for both private and public companies.
MS
Michael SullivanExecutive
JHJanet Huffman
Janet HuffmanChief Executive Officer & Chief Financial Officer
JP
James P. KellyChief Medical Officer
WP
William PeacockChief Clinical Officer

Board

RK
Robert KoskiBoard director
FT
Frederick TellingBoard director
AD
Alan DuntonBoard director
CP
Charles PopeBoard director

Reported raises · per SEC filings

Form D private placements

$19.9M disclosed across 6 of 8 rounds · 2016–2026

▶$850KraisedAug 2023 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alan DuntonDirector
  • Frederick TellingDirector
  • Kimberly MurphyExecutive Officer, Director
  • Janet HuffmanExecutive Officer
  • Charles PopeDirector
  • Robert KoskiDirector
Offering amount
$850K
Amount sold
$850K
Minimum investment
$100K
First sale
Aug 2023
Incorporated
Corporation, Florida
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.6MraisedMay 2020 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Charles PopeDirector
  • Michael SullivanExecutive Officer
  • Robert KoskiDirector
  • Frederick TellingDirector
  • Alan JoslynExecutive Officer, Director
  • Alan DuntonDirector
Amount sold
$4.6M
First sale
May 2020
Incorporated
Corporation, Florida
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.8MraisedApr 2018 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alan JoslynExecutive Officer, Director
  • Frederick TellingDirector
  • Charles PopeDirector
  • Robert KoskiDirector
  • Alan DuntonDirector
  • Michael SullivanExecutive Officer
Offering amount
$1.8M
Amount sold
$1.8M
Sales commissions
$144K
Placement agents
LADENBURG THALMANN & CO. INC.
First sale
Apr 2018
Incorporated
Corporation, Florida
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.7MraisedNov 2017 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Charles PopeDirector
  • Michael SullivanExecutive Officer
  • Frederick TellingDirector
  • Robert KoskiDirector
  • Alan DuntonDirector
  • Alan JoslynExecutive Officer, Director
Offering amount
$6.7M
Amount sold
$6.7M
First sale
Nov 2017
Incorporated
Corporation, Florida
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.3MraisedMay 2017 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert KoskiDirector
  • Frederick TellingDirector
  • Alan DuntonDirector
  • Charles PopeDirector
  • Michael SullivanExecutive Officer
  • Alan JoslynExecutive Officer, Director
Offering amount
$3M
Amount sold
$1.3M
First sale
May 2017
Incorporated
Corporation, Florida
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.7MraisedJul 2016 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Frederick TellingDirector
  • Alan DuntonDirector
  • Alan JoslynExecutive Officer, Director
  • Michael SullivanExecutive Officer
  • Robert KoskiDirector
  • Charles PopeDirector
Offering amount
$4.7M
Amount sold
$4.7M
First sale
Jun 2016
Incorporated
Corporation, Florida
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Simply Wall StSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.

Companies working in the same space as Oragenics.

Non-dilutive funding · 6 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2021$256.7K
National Science FoundationPhase II2008$500K
National Institutes of Health (NIH)National Institutes of HealthPhase I2007$100K
National Science FoundationPhase I2006$99.3K
National Institutes of Health (NIH)National Institutes of HealthPhase I2004$100K
National Science FoundationPhase I2004$100K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Advances Phase IIa Concussion Trial, Provides FDA and Listing Updates - InvestorWire (IW)investorwire.com · Aug 2026ORAGENICS PROVIDES INVESTOR UPDATEglobenewswire.com · May 2026Contact Us - Oragenics, Inc.oragenics.com · Apr 2026

Frequently asked questions

What does Oragenics do?
Oragenics develops treatments for concussion and traumatic brain injury, focusing on clinical development of therapeutic candidates. The company combines neuroscience expertise with healthcare operational leadership to advance solutions for brain injury treatment.
How much funding has Oragenics raised?
Oragenics has disclosed $19.9M raised across 6 of its 8 known rounds.
Where is Oragenics headquartered?
Oragenics is headquartered in Tampa, US.